Galderma reported record net sales of $3.134 billion for H1 2026 and raised full-year guidance, cementing its position as the largest pure-play aesthetics company by revenue. The upgrade reflects robust demand across its portfolio—BOTOX, Restylane, Sculptra, and Radiesse—and signals confidence in sustained pricing power and volume growth through year-end.
Business & M&A
Galderma Posts $3.1B H1 Sales, Raises 2026 Outlook
French-Swiss aesthetics leader reports record first-half revenue and upgrades full-year guidance.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
$3.1B H1 sales and raised full-year guidance.
For practice owners, Galderma's scale and guidance raise matter because the company's ability to raise prices, invest in loyalty programs, and expand indications (like Sculptra in India) sets the competitive tone for the entire market. Owners should expect continued pressure on per-unit toxin and per-syringe filler costs as Galderma leverages its distribution and rebate infrastructure to defend market share against Evolus and AbbVie. Monitor your Allergan Aesthetics (AbbVie) rebate terms closely; if Galderma's growth accelerates, AbbVie may respond with aggressive rebate restructuring.
Source: original report ↗
Frequently asked questions
How much revenue did Galderma make in the first half of 2026?
Galderma reported record net sales of $3.134 billion for H1 2026. This marks the company's strongest first-half performance and reinforces its position as the largest pure-play aesthetics company by revenue.
What does Galderma's price increase mean for my med spa costs?
Galderma's scale and pricing power will likely put continued pressure on per-unit toxin and per-syringe filler costs as the company leverages its distribution and rebate infrastructure. Practice owners should monitor rebate terms closely and expect potential aggressive restructuring from competitors like AbbVie in response.
Which products are driving Galderma's revenue growth?
Galderma's growth is fueled by robust demand across BOTOX, Restylane, Sculptra, and Radiesse. The company is also expanding indications for products like Sculptra into new markets such as India, which signals confidence in sustained volume growth through year-end.
Should I renegotiate my Allergan Aesthetics rebate agreement with AbbVie?
Yes—if Galderma's growth accelerates, AbbVie may respond with aggressive rebate restructuring to defend market share. Practice owners should proactively review their Allergan Aesthetics rebate terms now rather than wait for AbbVie to make unilateral changes.
What competitive threats should med spas watch for in 2026?
Galderma faces competition from Evolus and AbbVie, but its scale advantage allows it to invest heavily in loyalty programs and expand market access. Practice owners should monitor how AbbVie and Evolus respond to Galderma's guidance upgrade, as pricing and rebate wars often follow strong competitor earnings.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.